Furthermore, we demonstrated that all the IIM–cancer patients with anti‐CRT Ab had solid tumors and were more likely to have recurrent cancers compared to the anti‐CRT Ab‐negative patients (27.8% vs. 6.5%, P = 0.034); whereas the correlation between the cancer status and autoantibody profile was not observed in the patients with anti‐TIF‐1γ Ab (all P > 0.05, Table 3). This evidence concerns the gene TRIM33 and cancer.